Mavri A, Alessi M-C, Juhan-Vague I
Laboratory of Hematology, CHU Timone, Marseille, France.
J Intern Med. 2004 Apr;255(4):448-56. doi: 10.1046/j.1365-2796.2003.01288.x.
Insulin resistance syndrome (IRS) is associated with increased cardiovascular morbidity and mortality. IRS is becoming one of the major health problems as its prevalence grows rapidly. Accelerated atherothrombotic process in the IRS is attributed to metabolic abnormalities, inflammation and to impaired fibrinolysis due to increased plasma plasminogen activator inhibitor type 1 (PAI-1) levels. Proinflammatory cytokines may have an important role in PAI-1 overexpression, particularly in the adipose tissue. Studies in genetically modified mice indicate that PAI-1 might be involved in the aetiopathogenesis of obesity. Modifying PAI-1 expression by PAI-1 inhibitors may open a new field of research and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.
胰岛素抵抗综合征（IRS）与心血管疾病发病率和死亡率的增加相关。随着其患病率迅速上升，IRS正成为主要的健康问题之一。IRS中加速的动脉粥样硬化血栓形成过程归因于代谢异常、炎症以及由于血浆纤溶酶原激活物抑制剂1型（PAI-1）水平升高导致的纤维蛋白溶解受损。促炎细胞因子可能在PAI-1的过度表达中起重要作用，尤其是在脂肪组织中。对基因改造小鼠的研究表明，PAI-1可能参与肥胖的发病机制。通过PAI-1抑制剂改变PAI-1的表达可能会开辟一个新的研究领域，并可能揭示PAI-1在动脉粥样硬化和胰岛素抵抗过程中的真正作用。
